RxDoctor Payments Data

Valerie Hadam, MD

Endocrinology, Diabetes & Metabolism · Mayfield Hts, OHNPI 1811187750

Payments from drug & device makers

$12,200in general payments, 2019–2025

Across 806 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • Abbott$1K
  • AbbVie$695
  • Boehringer Ingelheim$694
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$12,192100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk192$2,256
Lilly USA, LLC101$1,296
Amgen(2 entities)66$1,134
Abbott54$1,122
AbbVie48$695
Boehringer Ingelheim47$694
AstraZeneca(2 entities)30$504
Sanofi-aventis U.S. LLC18$299
Dexcom, Inc.15$272
Vivus LLC15$250
Currax Pharmaceuticals LLC16$211
Merck14$204
Pfizer12$192
Xeris Pharmaceuticals, Inc.10$187
Mannkind Corporation10$185
Johnson & Johnson15$184
Bayer9$173
Insulet Corporation10$171
Shire North American Group Inc13$162
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$161
Antares Pharma, Inc.8$158
Corcept Therapeutics6$143
Novartis7$134
Medtronic(2 entities)5$131
Astellas Pharma US Inc6$120
IBSA Pharma Inc.7$113
Biohaven Pharmaceutical Holding Company Ltd.5$96
Radius Health, Inc.5$78
Neurocrine Biosciences, Inc.4$75
Lifescan, Inc.4$56
Aimmune Therapeutics, Inc.3$52
Nestle Healthcare Nutrition Inc.3$52
Acerus Pharmaceuticals Corporation2$43
Takeda Pharmaceuticals U.S.A., Inc.3$43
Amryt Pharma Holdings Ltd3$40
Sequel Med Tech, LLC1$39
Verity Pharmaceuticals Inc.2$37
Exact Sciences2$34
GSK2$34
Ascendis Pharma Endocrinology Inc2$34
Amneal Pharmaceuticals LLC2$30
Phathom Pharmaceuticals, Inc.3$29
Ultragenyx Pharmaceutical Inc.2$27
BETA Bionics, Inc.1$27
Averitas Pharma Inc.1$24
Genentech USA, Inc.1$22
Chiesi USA, Inc.1$19
Acella Pharmaceuticals, LLC1$18
Recordati_rare_diseases_inc.1$16
Dynavax Technologies Corporation1$16
Clarus Therapeutics Inc.1$16
Tandem Diabetes Care, Inc.1$15
Biohaven Pharmaceuticals, Inc.1$15
Phadia US Inc.1$13
Amarin Pharma, Inc.1$13
Sanofi Pasteur Inc.1$13
Nabriva Therapeutics, PLC1$12
Valeritas, Inc.1$12

How this compares

$12,200 in reported general payments places this provider in the 75th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$129,173
Medicare patients
624
Services billed
2,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide613$1,178,297
JardianceEmpagliflozin507$707,563
TrulicityDulaglutide363$677,760
MounjaroTirzepatide100$153,242
JanuviaSitagliptin Phosphate99$137,000
Tresiba Flextouch U-100Insulin Degludec151$111,376
FarxigaDapagliflozin Propanediol78$95,397
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog85$69,427
ProliaDenosumab40$69,114
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/741$59,565
Humulin R U-500 KwikpenInsulin Regular, Human13$56,295
Lantus SolostarInsulin Glargine,hum.Rec.Anlog306$46,866
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog28$44,200
Humalog Kwikpen U-100Insulin Lispro108$43,301
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog74$42,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,256$1,178,297613 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30$1,296$845,953513 claims
Boehringer IngelheimJardiance, Tradjenta$694$728,325522 claims
MerckJanuvia$204$137,00099 claims
AstraZenecaFarxiga$504$95,39778 claims
AmgenProlia$1,134$69,11440 claims
AbbVieSynthroid$695$25,418335 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$10,2611,075 claims
Sanofi-aventis U.S. LLCLantus$299$3,62216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Mayfield Hts

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →